Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF -

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are foundational therapy in patients with heart failure with reduced ejection fraction (HFrEF), yet underlying mechanisms of benefit

1528668326607695872

Circulation

#OriginalResearch Simpub #HeartFailure2022: Dapagliflozin #RCT using #metabolomics in HFrEF reveal key metabolic pathways, particularly altered ketone and fatty acid pathways with #SGLT2i @senthil_selv @svatishah @dukecardiology @MkosiborodMD #AHAJournals https://t.co/nmlPklUb1A https://t.co/nmlPklUb1A - view on twitter

More coverage: #AHAJournals #HeartFailure2022 #Metabolomics #OriginalResearch #RCT #SGLT2i

Read the full article here

See more from Circulation